Document Detail

Update on ethambutol optic neuropathy.
MedLine Citation:
PMID:  16907651     Owner:  NLM     Status:  MEDLINE    
Ethambutol optic neuropathy is a well-recognised adverse ocular event in patients who receive ethambutol for the treatment of mycobacterial infections. Much has been published on this condition; however, understanding of patient outcomes and the mechanism by which ethambutol optic neuropathy occurs, as well as data published in textbooks and reference books, tend to lag behind what is currently known. The purpose of this article is to update the clinician on what is currently accepted in regards to the clinical presentation of ethambutol optic neuropathy and what type of eye care should be provided to patients treated with this medication. In addition, new treatment recommendations are suggested to assist clinicians in complying with currently accepted standards of care.
Frederick W Fraunfelder; Alfredo A Sadun; Terry Wood
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  5     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-08-23     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  615-8     Citation Subset:  IM    
Casey Eye Institute, Oregon Health & Science University, 3375 S.W. Terwilliger Boulevard, Portland, OR 97239-4197, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antitubercular Agents / adverse effects*,  metabolism
Ethambutol / adverse effects*,  metabolism
Optic Nerve Diseases / chemically induced*,  physiopathology
Product Surveillance, Postmarketing
Reg. No./Substance:
0/Antitubercular Agents; 74-55-5/Ethambutol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The withdrawal of antiepileptic drugs in patients with non-epileptic seizures: safety considerations...
Next Document:  Cardiac dysfunction associated with trastuzumab.